A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
A Study of ASP1951 in Subjects with Advanced Solid Tumors
Sponsor: Astellas Pharma Global Development, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS2018
U.S. Govt. ID: NCT03799003
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The main purpose of the study is to determine at what dose the study drug (ASP1951) is safe and tolerated and how it is processed in the blood of subjects with tumors that cannot be removed (unresectable) or has spread (metastasized) to a different part of the body. When the safe dose is identified, it will be used to evaluate if the study drug treatment causes tumors to shrink in subjects. During this period, the subjects will be continuously assessed to determine if the study drug is safe and tolerable.
This study is closed
Investigator
Brian Henick, MD
Do You Qualify?
Do you have tumor(s) that cannot be removed (unresectable) or has spread (metastasized) to a different part of the body? Yes No
Are you willing to possibly undergo biopsies during the study? Yes No
Are you 18 years of age or older? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE